Mural Oncology
MURA

$3.46

0.29%

Market Cap: $59M

About: Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Employees: 107

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

8.12% less ownership

Funds ownership: 72.53% [Q1] → 64.41% (-8.12%) [Q2]

14% less funds holding

Funds holding: 99 [Q1] → 85 (-14) [Q2]

36% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 33

43% less capital invested

Capital invested by funds: $60M [Q1] → $34.2M (-$25.8M) [Q2]

54% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 26

68% less call options, than puts

Call options by funds: $6K | Put options by funds: $19K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$15

334%

upside

Avg. target

$15

334%

upside

High target

$15

334%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Rodman & Renshaw

Tony Butler

0 / 0 met price target

334%upside

$15

Buy

Initiated

28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about MURA published over the past 30 days

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on September 3, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of 21,500 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 11,500 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology to Present at Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participate at two upcoming investor conferences and take 1x1 meetings. A webcast of both presentations will be available at ir.muraloncology.com.

Mural Oncology to Present at Two Upcoming Investor Conferences

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on August 1, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of 13,000 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 7,000 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30.

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on July 1, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 15,470 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 8,330 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on June 3, the Company granted to two newly hired employees (i) non-statutory stock options to purchase an aggregate of 7,995 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 4,305 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in 2025 In April 2024, Mural presented preclinical data on its investigational engineered cytokine therapies targeting IL-18 and IL-12 and continues to expect candidate nominations for each program by the end of 2024 The company reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts WALTHAM, Mass. and DUBLIN, Ireland, May 14, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced financial results for the first quarter of 2024 and provided a business update.

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

See News Rankings